Perspective · 3 Nov 2025
Research articlePublished 2014
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Angiogenesis is essential for tumor growth and development of metastases in human breast cancer. Randomized studies have shown that bevacizumab (inhibitor of VEGF) combined with taxane-based regimens increases response rates and prolongs Progression-Free Survival (PFS) of patients with Metastatic Breast Cancer (MBC). However predictive or prognostic markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. In this retrospective analysis, we investigated the impact of traditional clinical and pathological features in order to identify the subgroups of patients who derive the greatest benefit from antiangiogenic-agents. Patients and methods: Retrospectively, we included consecutive patients treated with bevacizumab (10 mg/Kg on days 1 and 15) and paclitaxel (90 mg/m2, on days 1, 8 and 15) as first-line treatment for HER2-negative MBC at our Institution between June 2007 and December 2012. Results: 33 patients were included. Median age was 50 years (31-68). 78. 8%, 12.1% and 9.1% of patients had luminal B, triple negative and luminal A breast cancer, respectively. 66. 6% of patients had visceral disease. The overall response rate was 31.2%. Median PFS and overall survival (OS) were 7.7 months (range 1. 9-14.0 months) and 95.2 months (range 11.6-205.8 months), respectively. Univariate analysis highlighted a statistically significant relationship between PFS to the first line and the following factors: relapse-free survival (RFS12 months; p
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Chemotherapy: Open Access.
Opinion · 3 Nov 2025
Evaluation of Surgical Radiotherapy and Chemotherapy in the Treatment of Gynaecological Malignancies
Research article · 18 Aug 2025
Response Evaluation to Oxaliplatin-Based Adjuvant Chemotherapy after Curative Resection between Right and Left-Sided Stage II and III Colon Cancer: A Retrospective Survival Analysis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalChemotherapy: Open Access
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Mirco Pistelli”
- BylineArticles whose byline prints “Zelmira Ballatore”
- BylineArticles whose byline prints “Mariagrazia De Lisa”
- BylineArticles whose byline prints “Miriam Caramanti”
- BylineArticles whose byline prints “Alessandra Pagliacci”
- BylineArticles whose byline prints “Nicola Battelli”
- BylineArticles whose byline prints “Francesca Ridolfi”
- BylineArticles whose byline prints “Alfredo Santinelli”
